BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33997750)

  • 21. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
    He H; Mennone A; Boyer JL; Cai SY
    Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondria protection as a mechanism underlying the hepatoprotective effects of glycine in cholestatic mice.
    Heidari R; Ghanbarinejad V; Mohammadi H; Ahmadi A; Ommati MM; Abdoli N; Aghaei F; Esfandiari A; Azarpira N; Niknahad H
    Biomed Pharmacother; 2018 Jan; 97():1086-1095. PubMed ID: 29136945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thioredoxin reductase 1 regulates hepatic inflammation and macrophage activation during acute cholestatic liver injury.
    Shearn CT; Anderson AL; Miller CG; Noyd RC; Devereaux MW; Balasubramaniyan N; Orlicky DJ; Schmidt EE; Sokol RJ
    Hepatol Commun; 2023 Jan; 7(1):e0020. PubMed ID: 36633484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Phospho-c-Jun N-Terminal Kinase Expression on hepatocyte Necrosis and Autophagy in the Cholestatic Liver.
    Kwak BJ; Choi HJ; Kim OH; Kim KH; You YK; Lee TY; Ahn J; Kim SJ
    J Surg Res; 2019 Sep; 241():254-263. PubMed ID: 31035140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡.
    McDaniel K; Meng F; Wu N; Sato K; Venter J; Bernuzzi F; Invernizzi P; Zhou T; Kyritsi K; Wan Y; Huang Q; Onori P; Francis H; Gaudio E; Glaser S; Alpini G
    Hepatology; 2017 Feb; 65(2):544-559. PubMed ID: 27639079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADAM Metalloproteinase Domain 17 Regulates Cholestasis-Associated Liver Injury and Sickness Behavior Development in Mice.
    Almishri W; Swain LA; D'Mello C; Le TS; Urbanski SJ; Nguyen HH
    Front Immunol; 2021; 12():779119. PubMed ID: 35095853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis.
    Spatz M; Ciocan D; Merlen G; Rainteau D; Humbert L; Gomes-Rochette N; Hugot C; Trainel N; Mercier-Nomé F; Domenichini S; Puchois V; Wrzosek L; Ferrere G; Tordjmann T; Perlemuter G; Cassard AM
    JHEP Rep; 2021 Apr; 3(2):100230. PubMed ID: 33665587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic preconditioning protects BSEP/ABCB11
    Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
    J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation.
    Jang JH; Rickenbacher A; Humar B; Weber A; Raptis DA; Lehmann K; Stieger B; Moritz W; Soll C; Georgiev P; Fischer D; Laczko E; Graf R; Clavien PA
    Hepatology; 2012 Jul; 56(1):209-18. PubMed ID: 22290718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexamethasone decreases cholestatic liver injury via inhibition of intrinsic pathway with simultaneous enhancement of mitochondrial biogenesis.
    Tiao MM; Lin TK; Chen JB; Liou CW; Wang PW; Huang CC; Chou YM; Huang YH; Chuang JH
    Steroids; 2011 Jun; 76(7):660-6. PubMed ID: 21419148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
    Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
    JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigations of the total flavonoids extracted from flowers of Abelmoschus manihot (L.) Medic against α-naphthylisothiocyanate-induced cholestatic liver injury in rats.
    Yan JY; Ai G; Zhang XJ; Xu HJ; Huang ZM
    J Ethnopharmacol; 2015 Aug; 172():202-13. PubMed ID: 26133062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormesis in Cholestatic Liver Disease; Preconditioning with Low Bile Acid Concentrations Protects against Bile Acid-Induced Toxicity.
    Verhaag EM; Buist-Homan M; Koehorst M; Groen AK; Moshage H; Faber KN
    PLoS One; 2016; 11(3):e0149782. PubMed ID: 26950211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
    Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
    Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse.
    Kahraman A; Barreyro FJ; Bronk SF; Werneburg NW; Mott JL; Akazawa Y; Masuoka HC; Howe CL; Gores GJ
    Hepatology; 2008 Apr; 47(4):1317-30. PubMed ID: 18220275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bile Acid Toxicity and Protein Kinases.
    Engin A
    Adv Exp Med Biol; 2021; 1275():229-258. PubMed ID: 33539018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury.
    Tamaki N; Hatano E; Taura K; Tada M; Kodama Y; Nitta T; Iwaisako K; Seo S; Nakajima A; Ikai I; Uemoto S
    Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G498-505. PubMed ID: 18174271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Wang Y; Aoki H; Yang J; Peng K; Liu R; Li X; Qiang X; Sun L; Gurley EC; Lai G; Zhang L; Liang G; Nagahashi M; Takabe K; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2017 Jun; 65(6):2005-2018. PubMed ID: 28120434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NIM811 (N-methyl-4-isoleucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice.
    Rehman H; Ramshesh VK; Theruvath TP; Kim I; Currin RT; Giri S; Lemasters JJ; Zhong Z
    J Pharmacol Exp Ther; 2008 Dec; 327(3):699-706. PubMed ID: 18801946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
    Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
    Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.